EGFR and breast carcinoma: Thus, trastuzumab, pertuzumab, and ado-trastuzumabemtansine, which are given intravenously, are monoclonal antibodies that target the ErbB extracellular domains and are used for the treatment of ErbB2-positive breast cancer [120].